Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | IDE | P14735 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538889 | 1.00 | RAB9A (0.71) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5738051 | 0.99 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5738053 | 0.99 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8502308 | 0.98 | RAB9A (0.71) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5352269 | 0.95 | RAB9A (0.72) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8503121 | 0.94 | RAB9A (0.66) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8503345 | 0.92 | RAB9A (0.64) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8500179 | 0.92 | RAB9A (0.66) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3177868 | 0.92 | RAB9A (0.66) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8501939 | 0.92 | RAB9A (0.68) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114609268-A | Method for detecting related substances in dextral rabeprazole sodium bulk drug | 南京海纳医药科技股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-111714639-A | Composition comprising histamine release-promoting substance and benzimidazole derivative | 黄泳华 | 2020-09-29 | — | — | CN | claimed |
| CN-111084886-A | Composition comprising fatty acid or derivative thereof and benzimidazole derivative | 黄泳华 | 2020-05-01 | — | — | CN | claimed |
| CN-110964360-A | High-strength pigment red and preparation method thereof | 吴江山湖颜料有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-9228216-B2 | Synthesis of prazole compounds | CODEXIS, INC. (US) | 2016-01-05 | — | — | US | claimed |
| US-20150080579-A1 | Salts and Polymorphs of Dexrabeprazole | CIPLA LIMITED (IN) | 2015-03-19 | — | — | US | claimed |
| US-20150056668-A1 | SYNTHESIS OF PRAZOLE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-02-26 | — | — | US | claimed |
| US-8912337-B2 | Salts and polymorphs of dexrabeprazole | CIPLA LIMITED (IN) | 2014-12-16 | — | — | US | claimed |
| US-20130150588-A1 | Salts and Polymorphs of Dexrabeprazole | CIPLA LIMITED (IN) | 2013-06-13 | — | — | US | claimed |
| EP-2585450-A1 | SALTS AND POLYMORPHS OF DEXRABEPRAZOLE | Cilpa Limited (IN) | 2013-05-01 | — | — | EP | claimed |
| US-20080161579-A1 | Process for Synthesis of Proton Pump Inhibitors | CIPLA LIMITED (IN) | 2008-07-03 | — | — | US | claimed |
| EP-1818331-A1 | Process for the preparation of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole substantially free of sulfone impurity | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) | 2007-08-15 | — | — | EP | claimed |
| EP-1033129-B1 | ANTIMICROBIALS FOR TREATING PEPTIC ULCER | EISAI CO LTD (JP) | 2006-06-14 | — | — | EP | claimed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | claimed |
| EP-1270555-B1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA SA (ES) | 2004-08-25 | — | — | EP | claimed |
| US-6603009-B2 | Oxidation of a thioether to a sulfoxide using sodium percarbonate and a molybdenum salt as catalyst; making lansoprazole, omeprazole, rabeprazole, and pantoprazole | ESTEVE QUIMICA, S.A. (ES) | 2003-08-05 | — | — | US | claimed |
| EP-1270555-A1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA, S.A. (ES) | 2003-01-02 | — | — | EP | claimed |
| WO-2000027841-A1 | METHOD OF PREPARING SULFIDE DERIVATIVES | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2000-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161579-A1 | Process for Synthesis of Proton Pump Inhibitors | RAB29, HRH2, RAB7A | RAB9A 10/4885NPC1 4066/4885CYP2C9 33/4885 |
| US-20130150588-A1 | Salts and Polymorphs of Dexrabeprazole | CYP3A4, ATP1A4, CYP2D6 | RAB9A 1438/4885NPC1 2487/4885CYP2C9 92/4885 |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | RAB9A 3792/4885NPC1 4009/4885CYP2C9 44/4885 |
| US-20150080579-A1 | Salts and Polymorphs of Dexrabeprazole | CYP3A4, ATP1A4, CYP2D6 | RAB9A 1438/4885NPC1 2487/4885CYP2C9 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.